Figure 1.
Stress reactivity score change (A) and flow-mediated dilation (B), across postrandomization months 6 and 12, by treatment and participant age category: 45–49 (n = 53), 50–54 (n = 83), and 55–60 (n = 11). Caption: For both outcomes, a significant interaction between treatment and age was found (P < 0.05) such that age was associated with significantly lower FMD and greater stress reactivity among women on placebo (P < 0.01) but not among women on TE + IMP (P > 0.41). *P < 0.05
